Treatment Information

Back

Prostate Cancer treatment details. Biologic therapy.

University of Colorado Cancer Center, Denver, CO, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Denver, CO
Treatments:Biologic therapyHospital:University of Colorado Cancer Center
Drugs:Journal:Link
Date:Sep 2005

Description:

Patients: This Phase II study involved 18 men with hormone resistent prostate cancer. 13 had bone metastases.

Treatment: The treatment consisted of a biological therapy - Trastuzumab (Herceptin) which is a monoclonal antibody that is typically used to treat breast cancer.

Toxicity: 17% of patients experienced grade 4 toxicities. The authors did not list the grade 4 toxicities but mentioned a grade 3 cardiac toxicity and provided a list of 24 toxicities without specifying the grades (i.e. fatigue, nausea, dizziness, syncope, dyspnea, edema, chest pain, palpitations, etc.)

Results: The median overall survival was not reported and the authors concluded that Trastuzumab (Herceptin) as a single agent demonstrated poor efficacy in treating Hormone Refractory Prostate Cancer.

Correspondence: Albaha Barqawi, MB, FRCS



Back